Tuesday , November 21 2017
Home / Therapies / SGLT-2 Therapy Center (page 12)

SGLT-2 Therapy Center

Diabetes in Control is pleased to provide you with the latest insights and information on the Sodium-Dependent Glucose Transporter Two (SGLT-2) drug class to help optimize your practice. We hope you’ll benefit from the insights and share them with your colleagues. Thanks for all you’re doing to improve your patients’ lives and longevity!

Christophe Arbet-Engels, MD, Q10: Possibility of Combination Drugs with Empagliflozin

Dr. Christophe Arbet-Engels continues his discussion of the potential for combining the SGLT-2 inhibitor empagliflozin with other drugs down the road, and that they will certainly be exploring these otpions.  Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc. See more SGLT-2 Resources

Read More »

Christophe Arbet-Engels, MD, Q11: Is Empagliflozin Also Being Submitted Internationally?

Dr. Christophe Arbet-Engels explains that Boehringer Ingelheim will also be submitting empagliflozin internationally, and certainly in the EU, and that they will also look carefully at all possibilities to submit the drug to other international authorities. Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim …

Read More »

Christophe Arbet-Engels, MD, Q12: Diabetes Drug Efficacy in Different Populations

Dr. Christophe Arbet-Engels answer the question, “Do the Swiss get diabetes?” and, on a more serious note, explains that they are exploring different options for different patient populations to find the best treatment possible for each individual patient.   Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, …

Read More »

Discussion of Practical Implementation of SGLT-2’s with a Patient, Part 3

alt

In this week’s Homerun Slides, we continue our short series on introducing SGLT-2 inhibitor therapy to your patients. Topics this week include: Practical Clinical Approaches To Maximize Benefits and Minimize Risks… To download the complete set in PowerPoint format, just use this link: Discussion of Practical Implementation of SGLT-2’s with a Patient, …

Read More »